Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3366 - Analysis of gut microbiota in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoints blockers

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Non-Small Cell Lung Cancer

Presenters

FEIYU ZHANG

Citation

Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268

Authors

F. ZHANG1, N. Dong1, S. Gallach2, S. Calabuig Fariñas3, M. Mosqueda1, E. Escorihuela2, M. Meri4, F. De Asís4, A. Blasco5, J. Garde4, E. Jantus-Lewintre6, C. Camps7

Author affiliations

  • 1 Molecular Oncology Lab, Fundación de Investigación Hospital General Universitario de Valencia, 46014 - valencia/ES
  • 2 Molecular Oncology Lab-ciberonc, Fundación de Investigación Hospital General Universitario de Valencia, 46014 - valencia/ES
  • 3 Molecular Oncology Lab-ciberonc-dep. Of Pathology, Universitat De València, Fundación de Investigación Hospital General Universitario de Valencia, 46014 - valencia/ES
  • 4 Medical Oncology, Hospital General Universitario de Valencia, 46014 - valencia/ES
  • 5 Medical Oncology-ciberonc, Hospital General Universitario de Valencia, 46014 - valencia/ES
  • 6 Molecular Oncology Lab-ciberonc-department Of Biotechnology, Universidad Politécnica De Valencia, Fundación de Investigación Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 7 Medical Oncology-ciberonc-dep. Of Medicine, Universitat De València, Hospital General Universitario de Valencia, 46014 - valencia/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3366

Background

The microbiota community is considered as an organ of the human body. Recent studies have found that dysbiosis may have an impact on the interaction between immune regulation and tumor treatment. The main objective of this study is to characterize the gut microbiota in patients with non-small cell lung cancer (NSCLC) in advanced stages, and its relationship with obesity, smoking habits, clinical pathological features and response to treatment with immune-checkpoints blockers (ICB).

Methods

16S rRNA gene sequencing was performed on 48 stool samples from advanced NSCLC patients prior to treatment with ICB (PD-1 inhibitor and PD-L1 inhibitor). The database used for the taxonomic assignation was the SILVA_release_132. The parametric statistical analysis was performed in SPSS package (15.0). A p-value <0.05 was considered statistically significant for all analyzes.

Results

The average age of the 48 patients was (64±10 years), of which 36 patients were male, 27 patients present PD-L1 positive, 28 patients with smoking habits. 261 different genus were detected in all the samples, being Bacteroides 28.11%, Alistipes 6.58% and Prevotella 4.67% the more frequently found. Non-smokers presented significantly higher richness and diversity (Chao1 p = 0.001, Shannon p = 0.001, Simpson p = 0.03) compared with current and former smokers. Greater abundance of genus Blautia was associated with obesity (p = 0.043). In addition, according to histology, greater abundance of genus Odoribacter was observed in squamous cell carcinoma patients compared to adenocarcinoma (p = 0.04); and regarding stage, stage IIIB patients presented higher proportion of genus Lactobacillus than stage IV (p = 0.017).Patients with progression disease to the ICB treatment presented significantly higher abundance of genus Ruminococcaceae_UCG-013 (p = 0.019).

Conclusions

We have been demonstrated a potential relationship between the gut microbiota in NSCLC patients and clinical-pathological features, which requires confirmation in a larger study. The more relationship with the ICB is under evaluation and will be presented at the meeting. Funded by CB16/12/00350 from CIBEROnc, PI18/00226, and PI15-00753 from ISCIII.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Fundación Investigación Hospital General Universitario Valencia.

Funding

CIBEROnc, Instituto de Salud Carlos III.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.